Danazol as a second-line treatment for immune thrombocytopenic purpura

Eur J Haematol. 2019 Jan;102(1):97-98. doi: 10.1111/ejh.13184. Epub 2018 Nov 9.

Author

Jacques Zimmer¹

Affiliation

¹ Department of Infection and Immunity, Luxembourg Institute of Health, House of BioHealth, Esch-sur-Alzette, Luxembourg.

PMID: 30325539
DOI: 10.1111/ejh.13184

No abstract available

Publication types

Letter

MeSH terms

Danazol / administration & dosage
Danazol / adverse effects
Danazol / therapeutic use*
Humans
Purpura, Thrombocytopenic, Idiopathic / diagnosis
Purpura, Thrombocytopenic, Idiopathic / drug therapy*
Retreatment
Treatment Outcome

Substances

Danazol